Literature DB >> 808560

Consumption of classical complement components by heart subcellular membranes in vitro and in patients after acute myocardial infarction.

R N Pinckard, M S Olson, P C Giclas, R Terry, J T Boyer, R A O'Rourke.   

Abstract

Experiments were conducted to characterize the antibody-independent activation of complement in human serum by isolated human heart mitochondrial membranes in vitro and to determine whether similar patterns of complement consumption occurred in patients after acute myocardial infarction. Direct evidence for the interaction of C1 and heart mitochondrial membranes was obtained by mitochondria-C1 binding and elution experiments. Exposure of normal human sera to isolated human heart mitochondria at 37 degrees C resulted in the consumption of C1, C4, C2, and C3 without significant consumption of the terminal components of the complement system (C6 through C9). The consumption occurred in the absence of detectable anti-heart mitochondria autoantibody, was demonstrated to be calcium dependent, and was inhibited by either 0.01 M EDTA or ethylene glycol bis(bets-aminoethyl ether) N,N,N',N',-tetraacetic acid (EDTA). Although specific absorption of C1q from human sera inhibited the mitochondria-dependent activation of C4, C3 donsumption was not affected. These data indicate that the consumption of C4 and C2 likely occurred due to the mitochondrial membrane-mediated activation of C1, but that the consumption of the C3 did not necessarily involve either the classical or alternative complement pathways. After the in vitro characterization of the mitochondria-dependent activation of the complement system, additional studies were performed to determine whether similar consumption occurred in patients after acute myocaridal infarction. During a 72-h period after hospital admission significant decreases in C1, C4, and C3 occurred in six patients with recent chest pain but no evidence of acute myocardial infarction. These studies suggest that myocardial cell necrosis results in the release of subcellular membrane constituents capable of activating the complement system in the absence of detectable anti-heart autoantibodies; such activation may be responsible in part for the development of acute inflammation and evolution of the infarct size following coronary artery occulusion.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 808560      PMCID: PMC301923          DOI: 10.1172/JCI108145

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  14 in total

1.  The respiratory chain and oxidative phosphorylation.

Authors:  B CHANCE; G R WILLIAMS
Journal:  Adv Enzymol Relat Subj Biochem       Date:  1956

2.  Serologic tests for inflammation; serum complement, c-reactive protein and erythrocyte sedimentation rate in myocardial infarction.

Authors:  A J BOLTAX; E E FISCHEL
Journal:  Am J Med       Date:  1956-03       Impact factor: 4.965

3.  Immune hemolysis: a simplified method for the preparation of EAC'4 with guinea pig or with human complement.

Authors:  T Borsos; H J Rapp
Journal:  J Immunol       Date:  1967-08       Impact factor: 5.422

4.  Characterization of anti-heart mitochondria autoantibodies produced in dogs following myocardial infarction.

Authors:  R E Kelley; M S Olson; R N Pinckard
Journal:  Circ Res       Date:  1974-12       Impact factor: 17.367

5.  Antibody-independent activation of human C1 after interaction with heart subcellular membranes.

Authors:  R N Pinckard; M S Olson; R E Kelley; D H DeHeer; J D Palmer; R A O'Rourke; S Goldfein
Journal:  J Immunol       Date:  1973-05       Impact factor: 5.422

6.  Estimation of infarct size in man and its relation to prognosis.

Authors:  B E Sobel; G F Bresnahan; W E Shell; R D Yoder
Journal:  Circulation       Date:  1972-10       Impact factor: 29.690

7.  Sequential changes of plasma proteins after myocardial infarction.

Authors:  B G Johansson; C O Kindmark; E Y Trell; F A Wollheim
Journal:  Scand J Clin Lab Invest Suppl       Date:  1972

8.  Development of complement-fixing 19S, anti-heart mitochondria autoantibody, following myocardial infarction in dogs.

Authors:  R N Pinckard; M S Olson; R A O'Rourke; J D Palmer; R E Kelley; S Goldfein
Journal:  Circ Res       Date:  1971-09       Impact factor: 17.367

9.  Modification of myocardial infarction size after coronary occlusion.

Authors:  P R Maroko; E Braunwald
Journal:  Ann Intern Med       Date:  1973-11       Impact factor: 25.391

10.  The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats.

Authors:  J H Hill; P A Ward
Journal:  J Exp Med       Date:  1971-04-01       Impact factor: 14.307

View more
  44 in total

1.  Complement activation promotes muscle inflammation during modified muscle use.

Authors:  J Frenette; B Cai; J G Tidball
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

Review 2.  Complement in ischemia reperfusion injury.

Authors:  Niels C Riedemann; Peter A Ward
Journal:  Am J Pathol       Date:  2003-02       Impact factor: 4.307

Review 3.  The inflammatory response to cell death.

Authors:  Kenneth L Rock; Hajime Kono
Journal:  Annu Rev Pathol       Date:  2008       Impact factor: 23.472

4.  Adenovirus activates complement by distinctly different mechanisms in vitro and in vivo: indirect complement activation by virions in vivo.

Authors:  Jie Tian; Zhili Xu; Jeffrey S Smith; Sean E Hofherr; Michael A Barry; Andrew P Byrnes
Journal:  J Virol       Date:  2009-03-25       Impact factor: 5.103

Review 5.  Mechanisms of Cardiac Repair and Regeneration.

Authors:  Kathleen M Broughton; Bingyan J Wang; Fareheh Firouzi; Farid Khalafalla; Stefanie Dimmeler; Francisco Fernandez-Aviles; Mark A Sussman
Journal:  Circ Res       Date:  2018-04-13       Impact factor: 17.367

6.  Regulation of complement membrane attack complex formation in myocardial infarction.

Authors:  A Väkevä; P Laurila; S Meri
Journal:  Am J Pathol       Date:  1993-07       Impact factor: 4.307

7.  Immunohistochemical detection of terminal complement complex and S protein in normal and pre-eclamptic placentae.

Authors:  F Tedesco; O Radillo; G Candussi; A Nazzaro; T E Mollnes; D Pecorari
Journal:  Clin Exp Immunol       Date:  1990-05       Impact factor: 4.330

Review 8.  The role of complement activation in atherosclerosis.

Authors:  Florin Niculescu; Horea Rus
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

9.  Determining the one, two, three, or four long and short loci of human complement C4 in a major histocompatibility complex haplotype encoding C4A or C4B proteins.

Authors:  Erwin K Chung; Yan Yang; Kristi L Rupert; Karla N Jones; Robert M Rennebohm; Carol A Blanchong; C Yung Yu
Journal:  Am J Hum Genet       Date:  2002-09-10       Impact factor: 11.025

10.  Ibuprofen inhibits granulocyte responses to inflammatory mediators. A proposed mechanism for reduction of experimental myocardial infarct size.

Authors:  P J Flynn; W K Becker; G M Vercellotti; D J Weisdorf; P R Craddock; D E Hammerschmidt; R C Lillehei; H S Jacob
Journal:  Inflammation       Date:  1984-03       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.